公开(公告)号：US20180371099A1

公开(公告)日：2018-12-27

申请号：US16115343

申请日：2018-08-28

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： Richard BOURGON ,  David FABRIZIO ,  Gregg FINE ,  Garrett M. FRAMPTON ,  Priti HEGDE ,  Sanjeev MARIATHASAN ,  Philip J. STEPHENS ,  James Xin SUN ,  Roman YELENSKY

IPC: C07K16/28 ,  A61K39/395 ,  G16H50/30 ,  G16H20/10

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).

公开(公告)号：US20240190967A1

公开(公告)日：2024-06-13

申请号：US18237114

申请日：2023-08-23

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Marcin KOWANETZ ,  Gregg FINE ,  Sanjeev MARIATHASAN ,  Richard BOURGON

IPC: C07K16/28 ,  A61K39/00 ,  C12Q1/6886 ,  G01N33/574

CPC classification number: C07K16/2827 ,  C12Q1/6886 ,  G01N33/57407 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N2333/70532 ,  G01N2800/52

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

公开(公告)号：US20200031936A1

公开(公告)日：2020-01-30

申请号：US16655495

申请日：2019-10-17

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Marcin KOWANETZ ,  Gregg FINE ,  Sanjeev MARIATHASAN ,  Richard BOURGON

IPC: C07K16/28 ,  C12Q1/6886 ,  G01N33/574

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

公开(公告)号：US20220153861A1

公开(公告)日：2022-05-19

申请号：US17590918

申请日：2022-02-02

Applicant: Genentech, Inc. ,  Foundation Medicine, Inc.

Inventor： Richard BOURGON ,  David FABRIZIO ,  Gregg FINE ,  Garrett M. FRAMPTON ,  Priti HEGDE ,  Sanjeev MARIATHASAN ,  Philip J. STEPHENS ,  James Xin SUN ,  Roman YELENSKY

IPC: C07K16/28 ,  A61K39/395 ,  G16H50/30

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on somatic mutation levels of genes of the invention (e.g., somatic mutation levels in a tumor sample obtained from the patient).

公开(公告)号：US20180037655A1

公开(公告)日：2018-02-08

申请号：US15790680

申请日：2017-10-23

Applicant: Genentech, Inc.

Inventor： Priti HEGDE ,  Marcin KOWANETZ ,  Gregg FINE ,  Sanjeev MARIATHASAN ,  Richard BOURGON

IPC: C07K16/28 ,  C12Q1/68 ,  G01N33/574

CPC classification number: C07K16/2827 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/76 ,  C07K2319/30 ,  C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/158 ,  C12Q2600/178 ,  G01N33/57407 ,  G01N2333/70532 ,  G01N2800/52

Abstract: The present invention provides therapeutic and diagnostic methods and compositions for cancer, for example, bladder cancer. The invention provides methods of treating bladder cancer, methods of determining whether a patient suffering from bladder cancer is likely to respond to treatment comprising a PD-L1 axis binding antagonist, methods of predicting responsiveness of a patient suffering from bladder cancer to treatment comprising a PD-L1 axis binding antagonist, and methods of selecting a therapy for a patient suffering from bladder cancer, based on expression levels of a biomarker of the invention (e.g., PD-L1 expression levels in tumor-infiltrating immune cells in a tumor sample obtained from the patient) and/or based on the determination of a tumor sample subtype.

公开(公告)号：US20170051360A1

公开(公告)日：2017-02-23

申请号：US15346164

申请日：2016-11-08

Applicant: Genentech, Inc.

Inventor： Carlos BAIS ,  Richard BOURGON ,  Thomas SANDMANN

IPC: C12Q1/68 ,  A61K45/06 ,  A61K31/4188 ,  C07K16/22 ,  A61K39/395

CPC classification number: C12Q1/6886 ,  A61K31/4188 ,  A61K39/3955 ,  A61K45/06 ,  A61K2039/505 ,  C07K16/22 ,  C07K2317/24 ,  C07K2317/34 ,  C07K2317/56 ,  C12Q2600/106 ,  C12Q2600/158

Abstract: The invention provides methods and compositions to detect expression of one or more biomarkers for identifying and treating patients having glioblastomas who are likely to be responsive to VEGF antagonist therapy. The invention also provides kits and articles of manufacture for use in the methods.

Abstract translation: 本发明提供检测一种或多种生物标志物的表达的方法和组合物，用于鉴定和治疗可能对VEGF拮抗剂治疗有反应的成胶质细胞瘤的患者。 本发明还提供用于该方法的试剂盒和制品。